RT Journal Article
SR Electronic
T1 The RSV roadmap in children: Lessons learned, paths forward
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP S19
OP S25
DO 10.3949/ccjm.91.s1.04
VO 91
IS 9 suppl 1
A1 Negi, Ruchita
A1 Shabab, Jonathan
A1 Esper, Frank
YR 2024
UL http://www.ccjm.org/content/91/9_suppl_1/S19.abstract
AB Respiratory syncytial virus (RSV) is a threat to infants globally causing bronchiolitis and pneumonia. Despite decades of research, RSV outbreaks occur with only modest advancements in prevention or treatment. Vaccine development faced challenges because past attempts caused enhanced disease and treatment options demonstrated limited efficacy. Recent advancements, including maternal vaccines focusing on the prefusion form of the F glycoprotein are now showing significant benefits in preventing severe RSV-related illness in infants. Additionally, monoclonal antibodies offer prevention directly to newborns within 1 week of birth. These innovations have the potential to substantially change the impact of RSV.